Practıcal Aspects of 68Ga-Labelled Dota-Peptides for Peptide-Receptor Radionuclide Therapy

Journal of Engineering Technology and Applied Sciences
doi 10.30931/jetas.297622
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Journal of Engineering Technology and Applied Science

Related search

Peptide Receptor Radionuclide Therapy

Best Practice and Research in Clinical Gastroenterology
Gastroenterology
2005English

Peptide Receptor Radionuclide Therapy

2007English

New Developments in Peptide Receptor Radionuclide Therapy

Journal of Nuclear Medicine
MedicineNuclear MedicineRadiologyImaging
2018English

Pitfalls in the Response Evaluation After Peptide Receptor Radionuclide Therapy With [ 177 Lu-Dota 0 ,Tyr 3 ]Octreotate

Endocrine-Related Cancer
Cancer ResearchEndocrinologyOncologyMetabolismDiabetes
2017English

Diagnosis of Men-I Syndrome on 68Ga-Dotanoc PET-CT and Role of Peptide Receptor Radionuclide Therapy With 177Lu-Dotatate

International Journal of Endocrinology and Metabolism
EndocrinologyMetabolismDiabetes
2012English

Reply: Peptide Receptor Radionuclide Therapy in the United States

Journal of Nuclear Medicine
MedicineNuclear MedicineRadiologyImaging
2012English

Joint Guidance on Peptide Receptor Radionuclide Therapy in Neuroendocrine Tumors

Journal of Nuclear Medicine
MedicineNuclear MedicineRadiologyImaging
2013English

[68Ga]Ga-Dota-Toc: The First FDA-Approved 68Ga-Radiopharmaceutical for PET Imaging

Pharmaceuticals
Molecular MedicinePharmaceutical Science
2020English

Three-Dimensional Radiobiological Dosimetry of Kidneys for Treatment Planning in Peptide Receptor Radionuclide Therapy

Medical Physics
MedicineNuclear MedicineRadiologyImagingBiophysics
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy